PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: MARKET SEGMENTATION BY TYPE
Market segmentation by type
Comparison by type
Vitamin D-related rickets – Market size and forecast 2018-2023
Minerals-related rickets – Market size and forecast 2018-2023
Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America – Market size and forecast 2018-2023
Asia – Market size and forecast 2018-2023
Europe – Market size and forecast 2018-2023
ROW – Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
Competitive scenario
PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
F. Hoffmann-La Roche Ltd
Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi
PART 14: APPENDIX
Research methodology
List of abbreviations
Definition of vendors classification
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2018
Exhibit 17: Type – Market share 2018-2023 (%)
Exhibit 18: Comparison by type
Exhibit 19: Vitamin D-related rickets – Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Vitamin D-related rickets – Year-over-year growth 2019-2023 (%)
Exhibit 21: Minerals-related rickets – Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Minerals-related rickets – Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by type
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 28: North America – Year-over-year growth 2019-2023 (%)
Exhibit 29: Top 3 countries in North America
Exhibit 30: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in Asia
Exhibit 33: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 37: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in ROW
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Strategic alliances in global rickets treatment market
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: F. Hoffmann-La Roche Ltd – Vendor overview
Exhibit 49: F. Hoffmann-La Roche Ltd – Product segments
Exhibit 50: F. Hoffmann-La Roche Ltd – Organizational developments
Exhibit 51: F. Hoffmann-La Roche Ltd – Geographic focus
Exhibit 52: F. Hoffmann-La Roche Ltd – Segment focus
Exhibit 53: F. Hoffmann-La Roche Ltd – Key offerings
Exhibit 54: F. Hoffmann-La Roche Ltd – Key customers
Exhibit 55: Merck KGaA – Vendor overview
Exhibit 56: Merck KGaA – Business segments
Exhibit 57: Merck KGaA – Organizational developments
Exhibit 58: Merck KGaA – Geographic focus
Exhibit 59: Merck KGaA – Segment focus
Exhibit 60: Merck KGaA – Key offerings
Exhibit 61: Merck KGaA – Key customers
Exhibit 62: Novartis AG – Vendor overview
Exhibit 63: Novartis AG – Business segments
Exhibit 64: Novartis AG – Organizational developments
Exhibit 65: Novartis AG – Geographic focus
Exhibit 66: Novartis AG – Segment focus
Exhibit 67: Novartis AG – Key offerings
Exhibit 68: Novartis AG – Key customers
Exhibit 69: Pfizer Inc. – Vendor overview
Exhibit 70: Pfizer Inc. – Business segments
Exhibit 71: Pfizer Inc. – Organizational developments
Exhibit 72: Pfizer Inc. – Geographic focus
Exhibit 73: Pfizer Inc. – Segment focus
Exhibit 74: Pfizer Inc. – Key offerings
Exhibit 75: Pfizer Inc. – Key customers
Exhibit 76: Sanofi – Vendor overview
Exhibit 77: Sanofi – Business segments
Exhibit 78: Sanofi – Organizational developments
Exhibit 79: Sanofi – Geographic focus
Exhibit 80: Sanofi – Segment focus
Exhibit 81: Sanofi – Key offerings
Exhibit 82: Sanofi – Key customers
Exhibit 83: Validation techniques employed for market sizing
Exhibit 84: Definition of vendors classification
【掲載企業】
F. Hoffmann-La Roche Ltd, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi